Antony C. Mattessich is the President and CEO of Ocular Therapeutix, a company focused on developing innovative ocular therapies. He joined the company in July 2017 and has a history of strong performance. In 2023, he received total compensation of...

Antony C. Mattessich is the President and CEO of Ocular Therapeutix, a company focused on developing innovative ocular therapies. He joined the company in July 2017 and has a history of strong performance. In 2023, he received total compensation of approximately $3.28 million, which included a salary of $686,400 and a bonus tied directly to the company's performance. This marks a significant growth in his compensation and reflects the company's success during his tenure. His leadership is evident in the strategic decision-making that has led to Ocular Therapeutix's growth and innovation in the pharmaceutical sector. Mattessich has been actively trading company stocks, showing confidence in Ocular’s future, with notable trades peaking at over $9 million in a single month. His decisions have raised the stakes for Ocular Therapeutix as they navigate the development of new treatments. Before joining Ocular, he had significant experience at various companies, thereby bringing valuable insights to the team. His trajectory and decisions are watched closely by investors and analysts alike, as he continues to steer Ocular Therapeutix towards greater achievements.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Ocular Therapeutix CEOs

O

Antony C. Mattessich

Ex-CEO of Ocular Therapeutix

Sector of Economy

Healthcare

CEO of Ocular Therapeutix for

6 years 8 months (Jul 2017 - Apr 2024)

Previous Experience

Prior to his role at Ocular Therapeutix, Mr. Mattessich served in various leadership roles in the biopharmaceutical industry.

Rivals

Competitors/colleagues of Antony C. Mattessich

Holdings

See how much did Antony C. Mattessich make over time.

Antony Mattessich has been actively involved in trading Ocular Therapeutix stocks, signaling his confidence in the company's potential. Notably, in December 2020, he recorded a significant trading volume, with holdings peaking at around $2 million. In 2021, his trades fluctuated,...

Antony Mattessich has been actively involved in trading Ocular Therapeutix stocks, signaling his confidence in the company's potential. Notably, in December 2020, he recorded a significant trading volume, with holdings peaking at around $2 million. In 2021, his trades fluctuated, with his largest being over $1.35 million, illustrating his commitment to Ocular's growth. 2022 saw a considerable increase in activity, with his trades reaching as high as $4.72 million, showing a robust belief in the company's direction. However, by 2023, while his holdings still remained substantial, there was a noticeable adjustment, with transactions averaging around the $2 million mark. Overall, Mattessich's trading behavior reveals a keen insight into Ocular's business dynamics and future prospects.

Total Stock Sold

$172.72K

OCUL

$172.72K

38,007 OCUL shares

What if they kept their stock?

If Antony C. Mattessich didn't sell their stock, today they would have:
Extra OCUL38,007 shares worth $337.12K.
This is 95.19% and $164.41K more than what they got when they sold the stock.

Insider Trading

See recent insider trades of Antony C. Mattessich.

OCUL

$95.46K

OCUL at $4.86/share

Feb 3, 2024

Sale

OCUL

180,400 shares

OCUL

Feb 3, 2024

Received

OCUL

$90.77K

OCUL at $4.95/share

Jan 31, 2024

Sale

OCUL

$24.77K

OCUL at $3.81/share

Aug 30, 2023

Purchase

OCUL

$83.40K

OCUL at $4.24/share

Feb 6, 2023

Sale

OCUL

176,300 shares

OCUL

Jan 30, 2023

Received

OCUL

186,750 shares

OCUL

Feb 3, 2022

Received

OCUL

$49.45K

OCUL at $9.89/share

Aug 20, 2021

Purchase

OCUL

$112.40K

OCUL at $2.81/share

Jun 6, 2019

Purchase

OCUL

$119.00K

OCUL at $5.95/share

Aug 20, 2018

Purchase

Compensation History

See how much did Antony C. Mattessich make over time.

In 2023, Antony C. Mattessich earned a total compensation of $3,276,712 as the CEO of Ocular Therapeutix. His salary was $686,400, and he received a cash bonus of $459,545 based on the company's overall performance. A big part of his compensation came from vested stocks worth about $1.44 million, which highlights the alignment of his interests with those of shareholders. This level of compensation reflects not only his role in leading Ocular but also the company's growth and success during his leadership. Over the years, his compensation has seen a steady increase, showing the board's recognition of his contributions and the company's performance metrics.

Year

2023

Total Compensation

$2.59M

Salary

$686.40K

Board Justification

The compensation philosophy aligns with company performance, peer benchmarking, and retention strategies, focusing on attracting and retaining top talent.

Bonus

$459.55K

Board Justification

Discretionary annual cash bonuses based on overall corporate performance from the prior year, with Mr. Mattessich's bonus based solely on corporate performance.

Other

$3.00K

Board Justification

Includes 401(k) match and gross-ups for tax payments related to a group term life insurance policy.

Restricted Stock

$1.44M(684.04K RSU)

Board Justification

The stock awards that vested in 2023, reflecting the fair value of shares that became vested during the year.

Performance Metrics

Overall corporate performance from the prior year.

Other Ocular Therapeutix CEOs

Here are other CEOs of Ocular Therapeutix

Pravin U. Dugel, M.D.

CEO of Ocular Therapeutix

April 2024 - Present